The Wood on Clinuvel
Tuesday, 08 July, 2008
Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.
Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.
He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.
Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
